NL-OMON42995
Recruiting
Not Applicable
*The use of fecal calprotectin in detecting immunotherapy induced colitis and feasibility for the use of immunohistochemical markers in patients receiving checkpoint inhibitors*- a pilot study - COLIT-1
ederlands Kanker Instituut0 sites50 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- colitis
- Sponsor
- ederlands Kanker Instituut
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age \> 18 years
- •\- Starting with anti CTLA\-4 antibodies alone or in combination with anti PD\-1 antibodies for a malignancy
- •\- Signed informed consent
Exclusion Criteria
- •There are no exclusion criteria for participation in this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
The use of fecal calprotectin in detecting immunotherapy induced colitis and feasibility for the use of immunohistochemical markers in patients receiving checkpoint inhibitors’- a pilot studycolitisNL-OMON25248KI-AV50
Recruiting
Not Applicable
Study on the usefulness of fecal calprotectin in ulcerative colitis and the relevance of other biomarkerslcerative colitisJPRN-UMIN000052832Ehime University150
Completed
Not Applicable
Can fecal calprotectin be a predictive marker for refractoriness in patients with ulcerative colitis ?lcerative colitisJPRN-UMIN000024146Showa University, School of Medicine100
Completed
Not Applicable
Faecal calprotectin as a diagnostic test for IBD in children in primary careCrohn's diseaseinflammatory bowel diseaseulcerative colitis10017969NL-OMON34153niversitair Medisch Centrum Groningen218
Completed
Not Applicable
Relevance of fecal calprotectin as a biomarker to predict the outcome of Adalimumab therapy in Ulcerative Colitis patients.lcerative ColitisJPRN-UMIN000022104Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine54